部分多巴胺激动剂治疗精神分裂症。

Hospital medicine (London, England : 1998) Pub Date : 2005-05-01 DOI:10.12968/hmed.2005.66.5.18426

Mike Launer

{"title":"部分多巴胺激动剂治疗精神分裂症。","authors":"Mike Launer","doi":"10.12968/hmed.2005.66.5.18426","DOIUrl":null,"url":null,"abstract":"The emergence of partial dopamine agonists reinforces the argument for the dopamine hypothesis of schizophrenia. Aripiprazole (Abilify) is the first of these compounds for the treatment of schizophrenia to be launched in the UK. Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in the management of schizophrenia.","PeriodicalId":79637,"journal":{"name":"Hospital medicine (London, England : 1998)","volume":"66 5","pages":"300-3"},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.12968/hmed.2005.66.5.18426","citationCount":"2","resultStr":"{\"title\":\"Partial dopamine agonists in schizophrenia.\",\"authors\":\"Mike Launer\",\"doi\":\"10.12968/hmed.2005.66.5.18426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The emergence of partial dopamine agonists reinforces the argument for the dopamine hypothesis of schizophrenia. Aripiprazole (Abilify) is the first of these compounds for the treatment of schizophrenia to be launched in the UK. Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in the management of schizophrenia.\",\"PeriodicalId\":79637,\"journal\":{\"name\":\"Hospital medicine (London, England : 1998)\",\"volume\":\"66 5\",\"pages\":\"300-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.12968/hmed.2005.66.5.18426\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital medicine (London, England : 1998)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12968/hmed.2005.66.5.18426\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital medicine (London, England : 1998)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12968/hmed.2005.66.5.18426","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

部分多巴胺激动剂的出现强化了精神分裂症多巴胺假说的论点。阿立哌唑(Abilify)是这些用于治疗精神分裂症的化合物中第一个在英国上市的。阿立哌唑具有良好的疗效和良好的耐受性，表明它在精神分裂症的治疗中起着重要的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Partial dopamine agonists in schizophrenia.

The emergence of partial dopamine agonists reinforces the argument for the dopamine hypothesis of schizophrenia. Aripiprazole (Abilify) is the first of these compounds for the treatment of schizophrenia to be launched in the UK. Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in the management of schizophrenia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hospital medicine (London, England : 1998)

自引率

0.00%

发文量